AVTXAvalo Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $59K
- 87% YoY
- Operating margin
- -123601.7%
- 696% YoY
- EBITDA
- −$73M
- 6.2% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$85M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired231× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear2% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $5M | $18M | $2M | $441K | $59K | 87% |
| Operating income | −$82M | −$37M | −$27M | −$69M | −$73M | 6.4% |
| Net income | −$84M | −$42M | −$32M | −$35M | −$78M | 123% |
| Operating cash flow | −$71M | −$27M | −$31M | −$49M | −$51M | 4.9% |
| Capex | $113K | $95K | — | — | — | |
| Stock-based comp | $8M | $8M | $3M | $6M | $14M | 133% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $382K · 2
- Net
- −$382K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 2 | — |
| FY2024 | — | — | 1 | — |
| FY2023 | — | — | 1 | — |